ArticleMacromolecular bioscience2025
Orai1 is Required for Osteogenic Differentiation on Nanoparticulate Mineralized Collagen Glycosaminoglycan Materials.
Article in Macromolecular bioscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mineralized collagen scaffold pore architecture and glycosaminoglycan content biases anti-inflammatory macrophage phenotype.bioRxiv : the preprint server for biology · 2026Article
- Relyophilized collagen scaffold to improve handling and small molecule loading.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The role of the extracellular matrix (ECM) in guiding cell fate has spurred the development of synthetic, ECM-inspired regenerative biomaterials. We previously described a porous, open-cell foam composed of nanoparticulate mineralized collagen glycosaminoglycan (MC-GAG), capable of inducing in vitro osteogenesis of primary human mesenchymal stem cells (hMSCs) and in vivo skull regeneration without adding growth factors or expanded progenitor cells. This study investigated the role of store-operated calcium entry (SOCE) in MC-GAG activity by evaluating the impact of Orai1, the pore-forming subunit of the calcium release-activated channel. Compared to nonmineralized collagen glycosaminoglycan (Col-GAG), hMSCs cultured on MC-GAG exhibited increased Orai1 expression. Chemical inhibition of SOCE using MRS1845 reduced the expression of both gene and protein of osteogenic markers, as well as mineralization on MC-GAG, while MRS1845 exerted no effects on Col-GAG materials. Orai1 knockdown similarly inhibited matrix mineralization and expression of the late osteogenic marker, bone sialoprotein-2 (BSP2), on MC-GAG, whereas no effects were notable on Col-GAG. Orai1 knockdown reduced ERK1/2 phosphorylation, suggesting that the osteogenic effects of Orai1 functioned downstream of ERK1/2 pathways. These findings suggest Orai1 is necessary for osteoprogenitor maturation and matrix mineralization in MC-GAG-mediated osteogenic differentiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.